Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Hippokratia ; 26(1): 25-31, 2022.
Article in English | MEDLINE | ID: mdl-37124281

ABSTRACT

BACKGROUND: This study aimed to estimate the fine needle aspiration cytology's (FNAC) diagnostic accuracy in differentiating neoplastic from inflammatory lesions (Q1) and malignant from their benign counterparts (Q2). METHODS: We present a retrospective case series covering a single University Hospital and six attending head and neck surgeons over eight years (January 2011 to July 2017). We concentrated on adults with clinically suspected parotid gland lesions. We offered all patients FNAC biopsy preoperatively, and the final diagnosis was established based on the findings of the final histology. The FNAC and histology results were cross-tabulated in a 2 x 2 contingency table, from which we calculated the diagnostic accuracy, sensitivity, specificity, and positive and negative predictive values. RESULTS: From 212 consecutive patients reviewed, and after excluding thirteen cases (8 %) of valid but non-diagnostic FNAC, 161 cases (50 females and 111 males) fulfilled set eligibility criteria. The most common diagnosis was Warthin tumors (53 patients, 34 %), followed by pleomorphic adenomas (52 patients, 33.5 %). The sensitivity and specificity of FNAC in differentiating neoplastic from non-neoplastic lesions and in segregating malignant from benign conditions were estimated to be as high as 50 % and 97 %, and 98 % and 93 %, respectively. CONCLUSION: FNAC is moderately effective in differentiating non-neoplastic from neoplastic disease and highly accurate in selecting malignant lesions from benign ones. Although the lack of FNAC sensitivity can occasionally be problematic, it still comprises a valuable tool in salivary gland surgery. HIPPOKRATIA 2022, 26 (1):25-31.

2.
Arch Virol ; 157(5): 825-32, 2012 May.
Article in English | MEDLINE | ID: mdl-22294445

ABSTRACT

The E2 gene of human papilloma virus is expressed at the early stage of the viral life cycle, encoding the E2 transcription factor, and regulates the expression of E6 and E7 oncogenes. Disruption of E2 gene due to viral integration inhibits the transcriptional suppression of the HPV oncogenes, inducing cell proliferation. In the present study, a total of 22 HPV16-positive cytological specimens derived from high- and low-grade cervical intraepithelial lesions were investigated in order to identify sequence variations in the HPV16 E2 ORF. The E2 gene was amplified by PCR using external and internal overlapping sets of primers. Amplicons were cloned and sequenced. Disruption sites were detected in cervical samples diagnosed as high-grade cervical intraepithelial lesions. Moreover, sequence variations were identified in the E2 ORF and specific variations were associated with non-European variants such as African type I, African type II and Asian American. A total of three new sequence variations were identified at positions 2791, 2823 (transactivation domain) and 3361 (hinge region). Distinct phylogenetic branches were formed according to E2 analysis that characterized the different HPV16 variants. It was ascertained that non-European variants are circulating in the Greek population.


Subject(s)
DNA-Binding Proteins/genetics , Genetic Variation , Human papillomavirus 16/genetics , Oncogene Proteins, Viral/genetics , Papillomavirus Infections/virology , Uterine Cervical Dysplasia/virology , Base Sequence , DNA-Binding Proteins/chemistry , Female , Greece , Human papillomavirus 16/chemistry , Human papillomavirus 16/classification , Human papillomavirus 16/isolation & purification , Humans , Molecular Sequence Data , Oncogene Proteins, Viral/chemistry , Phylogeny , Protein Structure, Tertiary
3.
In Vivo ; 14(6): 767-71, 2000.
Article in English | MEDLINE | ID: mdl-11204497

ABSTRACT

BACKGROUND: This study was undertaken to investigate if low-dose dietary administration of tannic acid exerts its chemopreventive activity on hepatocarcinogenesis in male C3H mice through changes of plasminogen activator activity (PAA), plasminogen activator inhibition (PAI) or plasmin inhibition (Pl) in the liver of C3H hepatoma bearing male mice. MATERIALS AND METHODS: Tannic acid was administered in the drinking water of hepatoma bearing C3H mice, in a concentration of 0.0075% (group B), 0.015% (group C) and 0.03% (group D) for 9 months. PAA, PAI and PI were measured by spectrophotometric methods in macroscopically healthy liver regions. RESULTS: Tannic acid induced a decrease of PAA (53%) and an increase of PAIs (50%) in the livers of group D while tannic acid received mice showed a dramatic decrease in liver carcinomas incidence (0% vs 33.3% in the control group). CONCLUSION: The decrease of PAA in the liver of C3H hepatoma bearing male mice, might be correlated with the chemopreventive activity of tannic acid in hepatoma development.


Subject(s)
Astringents/pharmacology , Carcinoma, Hepatocellular/drug therapy , Hydrolyzable Tannins/pharmacology , Liver Neoplasms/drug therapy , Liver/metabolism , Plasminogen Activators/metabolism , Animals , Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/prevention & control , Liver/drug effects , Liver Neoplasms/metabolism , Liver Neoplasms/prevention & control , Male , Mice , Mice, Inbred C3H , Urokinase-Type Plasminogen Activator/metabolism
4.
Eur J Drug Metab Pharmacokinet ; 24(2): 183-9, 1999.
Article in English | MEDLINE | ID: mdl-10510748

ABSTRACT

Tannins are plant polyphenolic compounds that are contained in large quantities in food and beverages (tea, red wine, nuts, etc.) consumed by humans daily. It has been shown that various tannins exert broad cancer chemoprotective activity in a number of animal models. This review summarizes the recent literature regarding both the mechanisms involved, and the specific organ cancer models used in laboratory animals. An increasing body of evidence demonstrates that tannins act as both anti-initiating and antipromoting agents. In view of the fact that tannins may be of valid medicinal efficacy in human clinical trials, the present review attempts to integrate results from animal studies, and considers their possible application in humans.


Subject(s)
Chemoprevention/methods , Ellagic Acid/pharmacology , Hydrolyzable Tannins/pharmacology , Neoplasms/prevention & control , Tannins/pharmacology , Animals , Disease Models, Animal , Ellagic Acid/therapeutic use , Hydrolyzable Tannins/therapeutic use , Tannins/metabolism , Tannins/therapeutic use
5.
Cancer Lett ; 141(1-2): 57-62, 1999 Jul 01.
Article in English | MEDLINE | ID: mdl-10454243

ABSTRACT

Tannins are plant polyphenols comprising a heterogeneous group of compounds. Tannic acid is a common tannin found in tea, coffee, immature fruits, etc. and it has also been used as a food additive. An increasing body of experimental evidence supports the hypothesis that tannins exert anticarcinogenic activity in chemically induced cancers in animal models. In the present study, tannic acid was administered in very low doses in the drinking water of C3H male mice divided into three groups (75 mg/l, 150 mg/l and 300 mg/l). These animals carry a genetic defect and show a high incidence of spontaneous liver tumors (> 50%) at an age older than 12 months. The results showed a decrease in the overall incidence of hepatic neoplasms (adenomas plus carcinomas): 53.3% of animals in the control group developed hepatic neoplasms versus 33.3% in the group given a low dose of tannic acid, 26.6% in the group given a medium dose and 13.3% in the high dosage group. The difference was more pronounced in the animals with carcinomas: 4.44% of mice who received tannic acid developed carcinomas versus 33.3% of those in the control group. Tannic acid administration did not affect the PCNA labeling index of normal hepatocytes. It is concluded that tannic acid dietary intake in low doses can exert a strong dose-dependent chemoprotective activity against spontaneous hepatic neoplasm development in C3H male mice, most probably through antipromoting mechanisms.


Subject(s)
Adenoma/prevention & control , Anticarcinogenic Agents/therapeutic use , Carcinoma, Hepatocellular/prevention & control , Hydrolyzable Tannins/therapeutic use , Liver Neoplasms/prevention & control , Animals , Dietary Supplements , Dose-Response Relationship, Drug , Genetic Predisposition to Disease , Male , Mice , Mice, Inbred C3H , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...